Dendritic cell (DC)-mediated cross-presentation of exogenous antigens acquired in the periphery is critical for the initiation of CD8 + T cell responses. Several DC subsets are described in human tissues but migratory cross-presenting DCs have not been isolated, despite their potential importance in immunity to pathogens, vaccines, and tumors and tolerance to self. Here, we identified a CD141 hi DC present in human interstitial dermis, liver, and lung that was distinct from the majority of CD1c + and CD14 + tissue DCs and superior at cross-presenting soluble antigens. Cutaneous CD141 hi DCs were closely related to blood CD141 + DCs, and migratory counterparts were found among skin-draining lymph node DCs. Comparative transcriptomic analysis with mouse showed tissue DC subsets to be conserved between species and permitted close alignment of human and mouse DC subsets. These studies inform the rational design of targeted immunotherapies and facilitate translation of mouse functional DC biology to the human setting.
INTRODUCTION
Dendritic cells (DCs) are a heterogeneous population of rare leukocytes found in virtually all tissues, where they form a network of antigen-sensing and -presenting cells (Steinman, 2007) . The main role of DCs is to induce specific immunity against invading pathogens while maintaining tolerance to selfantigens. DC-mediated cross-presentation of exogenous antigens to CD8 + T cells is critical for the priming and activation of cellular immunity to viruses, tumors, and vaccines and to promote tolerance through the deletion of self-reactive CD8 + T cells (Kurts et al., 2010) .
By virtue of their location, migratory tissue DCs play a central role in the induction of immunity (Banchereau and Steinman, 1998; Allenspach et al., 2008) . Cross-presenting migratory DCs are functionally and anatomically specialized to acquire exogenous antigen in the tissues and initiate CD8 + T cell responses (Helft et al., 2010; del Rio et al., 2010) . Although cross-presenting capacity is also found in lymph node (LN)-resident DCs and may augment antigen presentation by migratory DCs (Shortman and Heath, 2010) , the latter are obligatory for efficient T cell priming (Allenspach et al., 2008) . Studies in mice have identified two lineages of migratory tissue DCs defined by differential expression of CD103 and CD11b. CD103 + DCs cross-present antigen to CD8 + T cells more effectively than do CD11b + DCs in a number of viral infection, tumor, and self-antigen models (Helft et al., 2010; del Rio et al., 2010) . Although these DCs play a critical role in immunity, no population with this activity has ever been isolated from human nonlymphoid organs. Human DCs of the interstitial dermis are the best described tissue DCs and comprise two subsets delineated by expression of CD1a and CD14 (Lenz et al., 1993; Nestle et al., 1993; Klechevsky et al., 2008; Haniffa et al., 2009 ). The surface markers bear no relation to mouse DCs and neither human DC subset excels in cross-presentation, so a functional homolog of the mouse CD103 + DC remains elusive (Collin et al., 2011) .
Several lines of evidence indicate that CD103
+ cross-presenting tissue DCs and CD8 + lymphoid-resident DCs together form a distinct DC lineage. Studies of genetic factors affecting DC development suggest that both are dependent upon the function of IRF8, Id2, and Batf3 (Aliberti et al., 2003; Edelson et al., 2010) and both arise from a common precursor, the pre-DC Liu et al., 2009) . Additional phenotypic and functional properties are found in common between CD103 + and CD8 + DCs including uptake of apoptotic cells via the lectin CLEC9A (Caminschi et al., 2008; Huysamen et al., 2008; Sancho et al., 2009 ), responsiveness to TLR3 stimulation (Jelinek et al., 2011) , and expression of the chemokine receptor XCR1 (Crozat et al., 2011) . The lectins DEC205 and langerin are also expressed on DCs of this lineage in a number of different sites (Contreras et al., 2010; Ginhoux et al., 2009) . Recent progress was made in identifying potential homologs of mouse DC subsets by examining human blood DCs. In addition to plasmacytoid DCs (pDCs), human blood harbors two subsets of CD11c + myeloid DCs: a major CD1c + (BDCA-1) population and a discrete CD141 + (thrombomodulin or BDCA-3)
subset (Dzionek et al., 2000; MacDonald et al., 2002; ZieglerHeitbrock et al., 2010) . Compared with CD1c + DCs, blood CD141 + DCs exhibit specialized cross-presenting function and express a number of markers associated with mouse CD8 + DCs (Jongbloed et al., 2010; Bachem et al., 2010; Crozat et al., 2010a; Poulin et al., 2010) including NECL2 (cellular adhesion molecule-1; CADM1) (Galibert et al., 2005) and CLEC9A (Caminschi et al., 2008; Huysamen et al., 2008; Sancho et al., 2009 ). Cloning of XCL1 and subsequent mapping of its receptor to a restricted set of DCs led to the discovery of XCR1 as a signature chemokine axis of cross-presenting DCs (Dorner et al., 2009; Crozat et al., 2010a) . Together with TLR3, these markers provide a concise functional profile of cross-presenting DCs that transcends species barriers. Although the function of human blood myeloid DCs is not known and they have no counterparts in mouse blood, these observations gave us further impetus to look for migratory cross-presenting DCs in human nonlymphoid tissues and to discover how they relate to known human tissue and blood populations. Here we identify the human tissue cross-presenting DC as a discrete population of CD141 Figure S1 ). CD141 lo CD11c lo cells on the plot of CD141 versus CD11c in skin preparations express high CD1a and langerin and are epidermal Langerhans cells (LCs) ( Figures 1A and S1 ).
The expression of CD1c, CD1a, and langerin is defined in Figure 1B In order to verify this approach and to allow comparison with previous studies on DCs migrating from human skin, we compared freshly digested and migrated skin preparations by gating cells according to relative expression of CD14 and CD1c ( Figure 1C) (Klechevsky et al., 2008; Haniffa et al., 2009 + DCs, these fractions were included to ensure that they were not also enriched for potential cross-presenting DCs (Figure 2A ).
Immunity
Human Migratory Cross-Presenting CD141 hi DCs Figure S1 . To corroborate the transcription profiles, we examined the response of dermal DC subsets to XCL1 in vitro ( Figure 2C ). XCL1 significantly and selectively increased the proportion of CD141 hi DCs migrating from explanted skin over 24 hr.
CD141
hi DCs also showed the highest expression of FLT3 and CLEC9A in blood, skin, and lung, whereas CD14 + DCs expressed the most M-CSFR and CX3CR1, markers associated with the monocyte and macrophage lineages. CD1c + DCs showed lower expression of FLT3 and CLEC9A and interme- diate levels of M-CSFR and CX3CR1, compared with CD141 hi DCs ( Figure 2D ). The morphology of sorted blood and skin DCs was examined by Giemsa staining of cytospin preparations ( Figure 2E ) and scanning electron microscopy (SEM) ( Figure 2F Although these do not express CLA and cannot be blood CD141 + DCs per se, they have a similar immature phenotype ( Figure 3C ). These data are consistent with the possibility that blood CD141 + DCs are the precursors of immature CD141 hi DCs, before acquiring CD1a, CD1c, activation antigens, and CCR7. To examine this possibility, we added sorted and labeled CD141 + blood DCs to a skin preparation and observed an upregulation of CD1a and CD1c in keeping with the tissue CD141 hi DC phenotype ( Figure 3D ). Furthermore, migrating CD141
hi DCs represented only the CD1a and CD1c mature fraction. This is at least consistent with a precursor-progeny relationship between blood CD141 + DCs and skin CD141 hi DCs. In mouse experiments, blood pre-DCs are not proliferating but go into cell cycle upon entry into the tissues (Figures 1 and 2 ) and express CCR7 (Figure 3 ), suggesting that they may migrate to LNs in vivo. To test this further we compared dermatopathic LN, which contains a high content of migratory DCs, with tonsil, a lymphoid tissue lacking afferent lymphatics ( Figure 4A ). Dermatopathic LNs contained an additional CD11c lo HLA-DR hi population. Based on the comparison of these two tissues and in keeping with the phenotype of migrating DCs in mouse LNs (Ohl et al., 2004) Figures 5A and 5B) . In blood, only CD141 + DCs were able to cross-present efficiently and required TLR3 stimulation with poly(I:C) or exposure to a maturation cocktail (containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).
Mature mo-DCs and mo-LCs were also able to cross-present HBsAg upon exposure to maturation cocktail but were refractory to TLR3 stimulus alone ( Figure 5A ). In the skin, superior crosspresenting capacity was found in CD141 hi DCs, compared with all other skin DC subsets, including LCs ( Figure 5B ). In keeping with their more activated status, cross-presentation by CD141 hi DCs occurred in the absence of stimulation, although TLR3 stimulation and maturation cocktail both increased this activity. CD1c + DCs showed little ability to cross-present antigens, even when the CD141 + fraction of these cells was specifically isolated and exposed to the maturation cocktail ( Figure 5B ). Hypothesizing that CD1c + and CD14 + DCs crosspresenting capacities could be induced by other stimuli, we exposed all DCs and LCs to a wide range of inflammatory stimuli (including maturation cocktail plus GM-CSF, LPS plus CD40 ligand, TLR8 agonist CL075, and mycobacterial extracts) but none of these conditions elicited cross-presentation at a greater level than with cytokine cocktail ( Figure 5 and data not shown). However, we cannot formally exclude that an untested condition could enhance CD1c + and CD14 + DCs cross-presenting capacities. The ability of CD141 hi DCs to cross-present was not a function of antigen uptake as indicated by the fact that all populations were able to take up near-equivalent PE-labeled HBsAg ( Figure 5C ). CD141 hi DCs were also the most active allostimulators of both CD4 + and CD8 + T cells; CD14 + DCs showed the least activity ( Figure 5D ). These results are consistent with the more activated status of CD141 hi DCs but did not indicate that they preferentially stimulated CD8 + T cells, compared with other DCs.
hi DCs Synthesize CXCL10 and TNF-a but Not
IL-12 or IL-23
Polarization of T cell responses by cytokine production is an important function of DCs. In the mouse, cross-presentation to CD8 + T cells usually occurs in the context of a Th1 cell response reinforced by IL-12 production (Reis e Sousa et al., 1997). However, no interstitial DC subset produced IL-12p70 even after stimulation, although IL-23p19 was synthesized in modest amounts. Both were easily detected in cultures of mo-DCs ( Figure 6A ). CD141
hi DCs were most efficient at TNF-a and CXCL10 production after TLR3 stimulation but produced very little IL-1, IL-6, IL-8, or IL-10. LCs also produced CXCL10. CD14 + DCs were the highest producers of IL-1, IL-6, and IL-10 whereas CD1c + DCs produced mainly IL-8 and IL-10 (Figure 6B ). Neither CD1c + DCs nor CD14 + DCs produced TNF-a or CXCL10 in response to all inflammatory conditions tested ( Figure 6B ) including LPS + CD40L, CL075, and mycobacterial extract (data not shown).
Transcriptome Mapping of Human and Mouse Nonlymphoid Tissue DCs
The alignment of DC subsets between mouse and human is of key importance in correlating human studies with mouse in vivo experiments (Guilliams et al., 2010) . The results described above suggest that CD141
hi DCs are functional homologs of mouse CD103 + DCs and that these are distinct from the major population of human CD1c + DCs and mouse CD11b + DCs. We sought to verify the conservation between species by an unbiased approach. In order to strengthen the analysis, we included human blood DCs and mouse lymphoid DCs. We sorted tissue DC subsets, blood DCs, and monocytes from human samples and generated gene signatures for each subset by removing tissue-specific expression patterns as detailed in the Supplemental Experimental Procedures. Sorted populations are shown in Table S1 . A hierarchical clustering of all the subsets used for signature generation shows close clustering of CD141 hi skin DCs with CD141 + blood DCs and CD1c + DCs from blood with CD1c + DCs from skin, suggesting the existence of two common DC subsets in blood and skin ( Figure 7A ).
Connectivity map analysis (CMAP) was performed comparing the skin CD141 hi DC gene set with the expression profile of other human DC and monocyte subsets (full details of bioinformatics analysis are described in Supplemental Experimental Procedures). The CMAP scores are scaled dimensionless quantities that indicate the degree of enrichment or ''closeness'' of one DC subset to another. CD141 + blood DCs show the highest enrichment with skin CD141 hi DCs, followed by pDCs, then CD1c DCs of skin and blood. CD14 + skin DCs and blood monocyte subsets both show inverse relationships with skin CD141 hi DCs ( Figure 7B ). This analysis also indicates similar enrichment scores between CD141 + and CD141 À fractions of CD1c + skin cells, suggesting that they are both components of the CD1c lineage.
Because 
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Human Migratory Cross-Presenting CD141 hi DCs and a pooled CD1c + DC signature from the two tissues. This was used to interrogate the relationship between these two human ''DC lineages'' and mouse DC subsets by further CMAP analysis ( Figure 7C ). Corresponding sorted mouse populations are shown in IL-1b, IFN-a, IFN-g (Albert et al., 1998; Klechevsky et al., 2008) . CD141
hi DCs in skin also express CCR7, migrate spontaneously, and are detectable as a distinct population within the migratory fraction of DCs in skin-draining lymph nodes. In vitro, CD141
hi DCs are most efficient at cross-presenting soluble antigens compared with other interstitial DCs and epidermal LCs. A wide range of inflammatory stimuli were tested, including TNF-a, IFN-a, GM-CSF, and LPS, with CD40 ligand, but failed to elicit efficient cross-presentation by other interstitial DCs or LCs. Monocytederived DCs and LCs were both able to cross-present in the assay but less so than CD141
hi DCs. Published data show that CD34-derived langerin + DCs are good at cross-presentation compared with CD14 + DCs (Klechevsky et al., 2008 
Human Migratory Cross-Presenting CD141 hi DCs CXCL10 or TNF-a from CD1c + and CD14 + DCs. We considered the possibility that inflammatory cytokine production might be required for cross-presentation by these cells, but the addition of exogenous TNF-a, IFN-a, and GM-CSF failed to confer cross-presenting capacity. LCs produced CXCL10 but did not cross-present efficiently. It remains a formal possibility that an untested condition will induce cross-presenting capacity in CD1c + and CD14 + DCs, but we did not find this among a wide range of physiological stimuli. (Acosta- Rodriguez et al., 2007) and are also major producers of XCL1. In addition to CD141 hi DCs, human tissues contain CD1c + DCs and CD14 + DCs, as previously described, notably in the skin (Lenz et al., 1993; Nestle et al., 1993; Haniffa et al., 2009 antigen can be used to identify cross-presenting tissue DCs in the appropriate context. Other markers such as CLEC9A and XCR1 are highly discriminatory, as emphasized by others (Caminschi et al., 2008; Huysamen et al., 2008; Sancho et al., 2009; Crozat et al., 2011) , but are difficult to stain on tissue cells.
To validate the identity of CD141 hi DCs, we showed that other CD141-expressing cells lacked the critical features of cross-presenting DCs in phenotypic and functional assays. A recent study isolated CD141 + DCs from human skin that also express CD14, produce IL-10, and induce regulatory T cells (Chu et al., 2012 (Jongbloed et al., 2010) , and in the spleen (Galibert et al., 2005; Poulin et al., 2010; Mittag et al., 2011) . With the exception of splenic DCs, functional studies were not undertaken with these lymphoid-derived populations (Galibert et al., 2005) . Work with humanized mice has also described the development of CD141 + DCs similar to blood CD141 + DCs in the spleen but not in nonlymphoid organs (Poulin et al., 2010) . CD141 + cells have been found in human lung, alveolar fluid, and kidneys but have not been characterized in detail (Demedts et al., 2005; Tsoumakidou et al., 2006; Fiore et al., 2008) . A recent report characterizing migratory and resident DCs from human lymph nodes concluded that CLEC9A + DCs were absent among migratory skin DCs (Segura et al., 2012) . In this study, CD1a À CD14 À DCs were examined for CLEC9A expression.
We have shown that skin migratory CD141 hi DCs coexpress CLEC9A but most are also positive for CD1a. It is therefore possible that CLEC9A + migratory DCs are excluded by gating only CD1a-negative cells.
Functional alignment of human and mouse DC subsets has been hampered by differences in surface marker expression and accessibility of equivalent sources. The identification of cross-presenting DCs as a specialized lineage first in mouse and now in humans has been predicated on a small number of specialized markers including NECL2 (cellular adhesion molecule-1; CADM1) (Galibert et al., 2005) , CLEC9A (Caminschi et al., 2008; Huysamen et al., 2008; Sancho et al., 2009) , XCR1 (Dorner et al., 2009; Crozat et al., 2010a) , and TLR3. These analyses focused on human blood but did not address nonlymphoid organs. In the tissues, neither CD1c + nor CD14 + DCs excel at cross-presentation and the CD14 + subset shares features of monocytes or macrophages (Haniffa et al., 2009 ) making it difficult to envisage comparisons with mouse CD103 + and CD11b + DCs. The identification of CD141 hi DCs therefore provided a missing link with which to compare human and mouse DC subsets of nonlymphoid origin and to explore the wider relationships between the species. For this purpose, we developed a modification of the functional genomic analysis by gene set enrichment analysis (GSEA), pioneered by Dalod and colleagues (Robbins et al., 2008; Crozat et al., 2010b Crozat et al., , 2011 . By eliminating probe sets that were differentially expressed between skin and blood, we were able to derive subset-specific signature transcriptomes that were not defined by arbitrary expression level thresholds. In order to compare these signatures, we adapted CMAP, an extension of the GSEA algorithm (Lamb et al., 2006) . This gives enrichment scores with a directional element assigning positive and negative scores to proximal and distal relationships, respectively. . Rather, our data indicate that langerin is more likely to be found on the CD1c + population, especially in liver and lung (Eisenwort et al., 2011 ; V.B., data not shown).
The finding that human CD14 + DCs are linked to monocyte populations in both mouse and human is intriguing and consistent with our initial observation that CD14 + DCs express M-CSFR and CX3CR1 but very little FLT3. They also express CD209 (DC-SIGN) in common with mo-DCs and have been found to be poor allostimulators in vitro (Klechevsky et al., 2008; Haniffa et al., 2009 (Lewis et al., 2011; Kasahara and Clark, 2012) . Consistent with this, we noted that CD4 + splenic DCs were much more closely linked to CD1c + DCs than were CD11b + DCs from tissues, which by analogy probably contain a monocyte-derived component. Altogether, our comparison of human and mouse DC subsets aligns the functional classification of DCs across species and allows clear inferences to be drawn between mouse and human. Targeting lectins associated with specific DC subsets is feasible in mice (Bonifaz et al., 2004; Dudziak et al., 2007) , primates, and humans (Flynn et al., 2011; Tsuji et al., 2011) . We anticipate that the identification of CD141 hi DCs will facilitate future rational vaccine design.
EXPERIMENTAL PROCEDURES
Cell Isolation and Culture Human samples were obtained in accordance with a favorable ethical opinion from Newcastle and Singapore Singhealth and National Health Care Group Research Ethics Committees. Normal skin was obtained from mammoplasty and breast reconstruction surgery. Lung and liver were obtained from peritumoral tissue. Tonsil and dermatopathic lymph nodes were obtained from tonsillectomy and lymph node diagnostic excisions. 300 mm whole skin dermatome sections, liver, and lung were cut into 0.5 cm squares and incubated with 0.8 mg/ml collagenase (Type IV, Worthington-Biochemical) in RPMI (PAA) with 10% FCS (AutogenBioclear) for 2 and 8 hr, respectively, or where stated mechanically dispersed. For LC isolation, skin was incubated in 1 mg/ml dispase (Invitrogen) for 1 hr to separate epidermis from dermis prior to collagenase treatment. Migrating cells were collected from whole skin cultured in RPMI with 10% FCS with or without 1 mg/ml XCL1 (R&D) or 0.1 mg/ml CCL3 (R&D). Viability was >90% by DAPI exclusion (Sigma).
Peripheral blood mononuclear cells were isolated by density centrifugation (Ficoll-Paque; GE Healthcare). CD3 + T cells were isolated from whole blood to >95% purity with Rosette-Sep isolation kit (StemCell Technologies). HLA-A*0201 hepatitis B surface antigen 183-91 (HBs183-91)-restricted CD8 + T cell clones were generated as previously described (Gehring et al., 2011) . Blood, lung, liver, and dermal DC subsets and epidermal LCs were isolated to >91% purity by fluorescence activated cell sorting (FACS) with a FACSAriaII (Becton Dickinson [BD] ). Monocyte-derived DCs (mo-DCs) were generated from magnetically isolated CD14 + monocytes (Miltenyi Biotec) cultured for 6 days with 50 ng/ml rGM-CSF and IL-4 (R&D).
Flow Cytometry
Flow cytometry was performed on a BDLSRII and FACSCanto and data analyzed with FlowJo (Treestar). FITC-coated dextran particles (MW70,000) were obtained from Sigma. Antibodies used are listed in Supplemental Experimental Procedures. For determination of DNA ploidy, FACS-sorted cells were fixed, permeabilized with BD Cytofix, Cytoperm, and Permwash, treated with 70% ice-cold ethanol for 2 hr, washed, and resuspended in 2 mg/ml DAPI solution. Cytospins were prepared from FACS-purified DCs and stained with the Hema 3 System according to manufacturer's protocol (Fisher Diagnostics). Images were analyzed with a Nikon Eclipse E800 microscope (Nikon). For scanning electron microscopy (SEM), sorted cells coated on poly-lysine (Sigma) glass coverslips were fixed in 2.5% glutaraldehyde, washed, treated with 1% osmium tetroxide (Ted Pella Inc.), and critical point dried (CPD 030, Bal-Tec). Glass coverslips were sputter-coated with platinum in a highvacuum sputtering device (SCD005 sputter coater, Bal-Tec) and imaged with a field emission scanning electron microscope (JSM-6701F, JEOL) at an acceleration voltage of 8 kV.
Dermal APC Stimulation with TLR Ligands FACS-purified dermal DCs were cultured in 96-well V-bottomed plates. Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS (Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ''cocktail'' containing 0.1 mg/ml LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (R&D), 50 ng/ml TNF-a (R&D), 3,000 IU/ml IFN-a (R&D), and 25 ng/ml IL-1b (R&D) with and without 50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and 20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were collected after 24 hr for cytokine analysis. TNF-a, IL-1b, IL-6, IL-10, IL12p70, and CXCL10 were detected with BD Cytometric Bead Arrays and analyzed with BD-FCAP Array software v1.0. IL-23p19 was measured by ELISA (R&D Quantikine ELISA kit).
Proliferation and T Cell Cytokine Production Assays 5,000 flow-sorted dermal DC subsets were cultured with 100,000 allogeneic CFSE-labeled CD3 + T cells in U-bottomed 96-well plates. Proliferation was assessed by CFSE dilution on day 6.
Cross-Presentation and ELISpot Assay 4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2 + donors were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech) with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) overnight in RPMI with 10% FCS. DCs were pulsed with HBs183-91 peptide (FLLTRILTI) for 3 hr. DCs were washed extensively and cultured with HLA-A*0201 HBs183-91-restricted CD8 + T cell clones in RPMI with 10% FCS and IFN-g production assessed after 18 hr by ELISpot. IFN-g spots were detected with an IFN-g antibody kit (Mabtech) and counted with CTL ImmunoSpot S5 UV Analyzer and ImmunoSpot Version 5 Professional Software.
Quantitative Real-Time PCR RNA was extracted with the RNeasy Micro Kit (QIAGEN) and reverse transcribed into cDNA by oligo-dT primer (Invitrogen) and Superscript First Strand Synthesis System (Invitrogen). cDNA was analyzed by real-time PCR with SYBR Green I Master Mix (Roche) with the LightCycler 480 System (Roche) for the following genes: GAPDH, XCR1, TLR3, and CADM1 (primer sequences are listed in Supplemental Experimental Procedures). Details of transcriptomic analysis are available in Supplemental Experimental Procedures.
Statistical Analyses
All statistical analyses were performed with Prism 5.0 (GraphPad Software). All p values are two-tailed.
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